Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
Subscribe To Our Newsletter & Stay Updated
